Coating calcifications

Inositec AG aims to halt vascular calcification in patients with chronic kidney disease by making analogs of the calcium chelator inositol hexaphosphate that are safer and more drug-like than the natural product.

According to co-founder and CEO Mattias Ivarsson, research over the last 10 years has linked poor CV outcomes in the chronic kidney disease (CKD) population to development of vascular calcification, a process that occurs when high concentrations of calcium phosphate in the blood trigger formation of mineral deposits in the vascular wall. Over time, buildup of the deposits causes vascular stiffening and occlusions...